A new era in prostate cancer detection is emerging with the EpiSwitch® PSE blood test, a highly accurate tool that enhances early diagnosis while significantly cutting false positives. Now covered by Bupa as a pre-biopsy test, PSE has demonstrated 94% accuracy and a leading 93% positive predictive value in distinguishing cancer, offering patients and clinicians a powerful alternative to PSA testing.
Clinicians can conveniently order the blood work before or during patient consultations, making integration into existing care pathways seamless. With its ability to provide greater confidence in decision-making before a biopsy, EpiSwitch® PSE represents a major advance in personalised care.
Robin Clark, Medical Director for Bupa Insurance, said: "We're pleased to partner with Oxford BioDynamics to cover the advanced EpiSwitch PSE test. The PSE provides a more accurate path to diagnosing prostate cancer, where getting an early diagnosis can make the disease nearly completely survivable."
FURTHER INFORMATION:
For more, visit: www.94percent.com
Contact: Bartu Ahiska PhD Snr. Dir. Commercial,
Oxford BioDynamics plc
E: bartu.a@myobdx.com
